- NovoCare® Pharmacy provides direct-to-patient,
convenient home shipments of all dose strengths of
Wegovy® at a reduced cost of $499 per month for cash-paying patients
- While 90% of patients taking Wegovy ® have a
co-pay of $0 to $25 per month, this offer was designed to support
cash-paying patients without insurance coverage
- Amidst the dangers of fake or illegitimate compounded
"semaglutide," NovoCare® Pharmacy offers reliable access
to authentic, FDA-approved Wegovy® in our once-weekly,
single-dose pen
PLAINSBORO, N.J., March 5,
2025 /PRNewswire/ -- As part of its ongoing efforts
to ensure patients who need Wegovy® (semaglutide)
injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access it,
Novo Nordisk launched NovoCare® Pharmacy, a
direct-to-patient delivery option that offers cash-paying patients
all dose strengths of Wegovy® at a reduced cost of
$499 per month. This offer is
available for uninsured patients or eligible patients with
commercial insurance who do not have coverage for obesity
medicines. NovoCare® Pharmacy expands the company's
toolkit of offerings to meet the diverse needs of people living
with obesity. This announcement follows the recent FDA decision
that the shortage of this medicine is resolved, with all dose
strengths of Wegovy® meeting or exceeding both current
and projected U.S. demand.
"Novo Nordisk continues to advance solutions for patients that
improve affordability and access to our medicines, whether they
have insurance or not. Today, over 55 million people in the U.S.
have coverage specifically for weight management medicines, and 90%
of Wegovy® patients with coverage pay $0 to $25 a month
for Wegovy®," said Dave
Moore, Executive Vice President, U.S. Operations and Global
Business Development and President of Novo Nordisk Inc. "With
NovoCare® Pharmacy, patients and prescribers alike have
another option that provides convenient access to all doses of
real, FDA-approved Wegovy® at a reduced cost in our
high-quality pen."
NovoCare® Pharmacy provides cash-paying patients who
have been prescribed Wegovy® with the ability to
schedule shipments of their Wegovy® prescriptions
directly to their home. These home shipments are fulfilled by
CenterWell Pharmacy, a six-time Specialty Pharmacy Patient Choice
award winner for best-in-class customer satisfaction and commitment
to patient care. Beyond convenient home delivery,
NovoCare® also supports patients with benefit
verification, refill reminders, and access to live support from a
NovoCare® case manager. More information about
NovoCare® Pharmacy is available at NovoCare.com
Additionally, NovoCare® Pharmacy offers patients
access to authentic, FDA-approved Wegovy®, helping to
avoid the significant risks that can be posed by the compounding
marketplace, as warned by respected organizations, experts in the
medical community, and the FDA. With an FDA-approved medicine
like Wegovy®, healthcare professionals and patients can
have clarity and confidence in knowing the medicine they are using
has undergone rigorous review for safety, effectiveness, and
quality. In the near future, the overall savings offer for
Wegovy® will be updated so that cash-paying
patients who use traditional retail pharmacies will also benefit
from this lower price.
Novo Nordisk is continuing to take multiple proactive measures
to keep patients safe. More information can be found on
semaglutide.com.
About Wegovy® (semaglutide) injection 2.4
mg
What is Wegovy®?
WEGOVY®
(semaglutide) injection 2.4 mg is an injectable prescription
medicine used with a reduced calorie diet and increased physical
activity:
- to reduce the risk of major cardiovascular events such as
death, heart attack, or stroke in adults with known heart disease
and with either obesity or overweight.
- that may help adults and children aged 12 years and older with
obesity, or some adults with overweight who also have
weight-related medical problems, to help them lose excess body
weight and keep the weight off.
Wegovy® contains semaglutide and should not be used
with other semaglutide-containing products or other
GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for
use in children under 12 years of age.
Important Safety Information
What is the most important information I should know about
Wegovy®? Wegovy® may cause serious side
effects, including:
- Possible thyroid tumors, including cancer. Tell
your healthcare provider if you get a lump or swelling in your
neck, hoarseness, trouble swallowing, or shortness of breath. These
may be symptoms of thyroid cancer. In studies with rodents,
Wegovy® and medicines that work like Wegovy®
caused thyroid tumors, including thyroid cancer. It is not known if
Wegovy® will cause thyroid tumors or a type of thyroid
cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Wegovy® if you or any of your family
have ever had a type of thyroid cancer called medullary thyroid
carcinoma (MTC) or if you have an endocrine system condition called
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Do not use Wegovy® if:
- you or any of your family have ever had a type of thyroid
cancer called medullary thyroid carcinoma (MTC) or if you have
an endocrine system condition called Multiple Endocrine Neoplasia
syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or
any of the ingredients in Wegovy®
Before using Wegovy®, tell your healthcare
provider if you have any other medical conditions, including if
you:
- have or have had problems with your pancreas or kidneys
- have type 2 diabetes and a history of diabetic retinopathy
- have or have had depression, suicidal thoughts, or mental
health issues
- are scheduled to have surgery or other procedures that use
anesthesia or deep sleepiness (deep sedation)
- are pregnant or plan to become
pregnant. Wegovy® may harm your unborn baby. You
should stop using Wegovy® 2 months before you plan to
become pregnant
- are breastfeeding or plan to breastfeed. It is not known
if Wegovy® passes into your breast milk
Tell your healthcare provider about all the medicines you
take, including prescription and over-the-counter medicines,
vitamins, and herbal supplements. Wegovy® may affect the
way some medicines work and some medicines may affect the way
Wegovy® works. Tell your healthcare provider if you are
taking other medicines to treat diabetes, including sulfonylureas
or insulin. Wegovy® slows stomach emptying and can
affect medicines that need to pass through the stomach quickly.
What are the possible side effects of
Wegovy®?
Wegovy® may cause serious
side effects, including:
- inflammation of your pancreas (pancreatitis). Stop
using Wegovy® and call your healthcare provider right
away if you have severe pain in your stomach area (abdomen) that
will not go away, with or without vomiting. You may feel the pain
from your abdomen to your back
- gallbladder problems. Wegovy® may cause
gallbladder problems, including gallstones. Some gallstones may
need surgery. Call your healthcare provider if you have symptoms,
such as pain in your upper stomach (abdomen), fever, yellowing of
the skin or eyes (jaundice), or clay colored stools
- increased risk of low blood sugar (hypoglycemia), especially
those who also take medicines for diabetes such as insulin
or sulfonylureas. This can be a serious side effect.
Talk to your healthcare provider about how to recognize and treat
low blood sugar and check your blood sugar before you start and
while you take Wegovy®. Signs and symptoms of low blood
sugar may include dizziness or light-headedness, blurred vision,
anxiety, irritability or mood changes, sweating, slurred speech,
hunger, confusion or drowsiness, shakiness, weakness, headache,
fast heartbeat, or feeling jittery
- kidney problems (kidney failure). In people who
have kidney problems, diarrhea, nausea, and vomiting may cause a
loss of fluids (dehydration), which may cause kidney problems to
get worse. It is important for you to drink fluids to help reduce
your chance of dehydration
- severe stomach problems. Stomach problems, sometimes
severe, have been reported in people who use Wegovy®.
Tell your healthcare provider if you have stomach problems that are
severe or will not go away.
- serious allergic reactions. Stop using
Wegovy® and get medical help right away, if you have any
symptoms of a serious allergic reaction, including swelling of your
face, lips, tongue, or throat; problems breathing or swallowing;
severe rash or itching; fainting or feeling dizzy; or very rapid
heartbeat
- change in vision in people with type 2
diabetes. Tell your healthcare provider if you have
changes in vision during treatment with Wegovy®
- increased heart rate. Wegovy® can increase
your heart rate while you are at rest. Tell your healthcare
provider if you feel your heart racing or pounding in your chest
and it lasts for several minutes
- depression or thoughts of suicide. You should pay
attention to any mental changes, especially sudden changes in your
mood, behaviors, thoughts, or feelings. Call your healthcare
provider right away if you have any mental changes that are new,
worse, or worry you
- food or liquid getting into the lungs during surgery or
other procedures that use anesthesia or deep sleepiness (deep
sedation). Wegovy® may increase the chance of
food getting into your lungs during surgery or other procedures.
Tell all your healthcare providers that you are taking
Wegovy® before you are scheduled to have surgery or
other procedures
The most common side effects of Wegovy® may
include: nausea, diarrhea, vomiting, constipation, stomach
(abdomen) pain, headache, tiredness (fatigue), upset stomach,
dizziness, feeling bloated, belching, low blood sugar in people
with type 2 diabetes, gas, stomach flu, heartburn, and runny nose
or sore throat.
Please see Medication Guide and Prescribing Information,
including Boxed Warning, for Wegovy® at
https://www.novo-pi.com/wegovy.pdf
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been
making innovative medicines to help people with diabetes lead
longer, healthier lives for more than 100 years. This heritage has
given us experience and capabilities that also enable us to drive
change to help people defeat other serious chronic diseases such as
obesity, rare blood, and endocrine disorders. We remain steadfast
in our conviction that the formula for lasting success is to stay
focused, think long-term, and do business in a financially,
socially, and environmentally responsible way. With U.S.
headquarters in New Jersey and
commercial, production, and research facilities in seven states
plus Washington DC, Novo Nordisk
employs approximately 8,000 people throughout the country. For more
information, visit novonordisk-us.com, Facebook, Instagram, and
X.
Novo Nordisk is committed to the responsible use of our
semaglutide-containing medicines which represent distinct products
with different indications, dosages, prescribing information,
titration schedules, and delivery forms. These products are not
interchangeable and should not be used outside of their approved
indications. Learn more at semaglutide.com.
About CenterWell
CenterWell is a leading health care
services business focused on creating integrated and differentiated
experiences that put our patients at the center of everything we
do. The result is high quality health care that is accessible,
comprehensive, and, most of all, personalized. CenterWell is the
largest provider of senior-focused primary care, one of the leading
providers of home health care, and a leading integrated home
delivery, specialty, hospice, and retail pharmacy. CenterWell
Pharmacy's home delivery pharmacy services are designed to provide
safe, convenient, and affordable access to medications, while
supporting adherence to treatment plans.
CenterWell is part of Humana Inc. Learn more about what we offer
at CenterWell.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html
SOURCE NOVO NORDISK INC.
